What Is BPC-157? Structure, Mechanisms and Research Status

Q: What is BPC-157?

BPC-157 is a synthetic pentadecapeptide (15 amino acids, sequence GEPPPGKPADDAGLV) corresponding to part of a protein described in human gastric juice. It has been studied extensively in animal and cell models of tissue injury.

Q: What does BPC stand for?

BPC stands for 'body protection compound', the name given by the Zagreb group that first described the parent protein. '157' identifies the particular 15-residue fragment.

Q: How is BPC-157 thought to work?

Cell and animal studies link it to VEGFR2–Akt–eNOS signalling (angiogenesis), to increased growth hormone receptor expression in tendon fibroblasts, and to fibroblast migration via FAK–paxillin. No single receptor has been identified.

Q: Has BPC-157 been tested in humans?

Only in small, uncontrolled pilot studies. A 2026 systematic review found three studies with 30 participants in total and rated the certainty of evidence as very low.

Q: Is BPC-157 an approved drug?

No. It has no marketing approval in the US or EU, and a 2026 review notes that there is no validated pharmaceutical formulation and no completed Phase II trial.

BPC-157 is a synthetic 15-amino-acid peptide (GEPPPGKPADDAGLV) that corresponds to a fragment of a protein described in human gastric juice. Over three decades it has been studied in a large number of rodent and cell models of tissue injury. Human data, however, remain limited to a handful of small pilot studies, and it is not an approved medicine anywhere in the US or EU.

For laboratory research use only. The compounds discussed are not approved for human or veterinary use and are not drugs, foods or cosmetics. This article summarises published research and is not medical advice.

Key points

Pentadecapeptide, 1419.5 g/mol; first described by researchers at the University of Zagreb.
Proposed mechanisms include VEGFR2–Akt–eNOS signalling, growth hormone receptor up-regulation and fibroblast migration.
Plasma half-life in rats and dogs is under 30 minutes.
Most evidence comes from animal models; human evidence is rated very low certainty.
No validated pharmaceutical formulation exists.

Quick facts

Property	Value
Sequence	Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Molecular formula	C₆₂H₉₈N₁₆O₂₂
Molecular weight	1419.5 g/mol (PubChem CID 9941957)
Name	“Body protection compound” fragment 157
Net charge at neutral pH	Acidic (three acidic residues vs one lysine)
Plasma half-life (rat, dog)	<30 min (He et al., 2022)
Regulatory status	Investigational; not approved in the US or EU

Lot-specific HPLC and MS data are published on the BPC-157 research peptide page.

Origin and early research

The parent protein was isolated from gastric juice by a group at the University of Zagreb, and BPC-157 was identified as a stable active fragment. In a 2003 rat study of transected Achilles tendon, the same group reported better biomechanical, functional and histological outcomes in BPC-157-treated animals than in controls over 14 days. They also observed stimulation of tendocyte growth in vitro (Staresinic et al., 2003). That paper noted that the peptide was then in clinical development for inflammatory bowel disease under the code PL 14736. No such program has led to an approved product.

Proposed mechanisms

No dedicated receptor for BPC-157 has been identified. Mechanistic work has instead mapped downstream pathways in specific models:

Pathway	Model	Finding	Study
VEGFR2–Akt–eNOS	Chick CAM, endothelial cells, rat ischemic hind limb	Increased vessel density and VEGFR2 expression (not VEGF-A); VEGFR2 internalisation and time-dependent pathway activation	Hsieh et al., 2017
Growth hormone receptor	Rat Achilles tendon fibroblasts	GHR among the most up-regulated genes on microarray; dose- and time-dependent increase at mRNA and protein level	Chang et al., 2014
FAK–paxillin, F-actin	Tendon explants and fibroblasts	Faster explant outgrowth, migration and spreading; improved survival under H₂O₂; no direct effect on proliferation	Chang et al., 2011

A 2025 narrative review summarises these pathways, VEGFR2 and nitric oxide signalling via Akt–eNOS together with ERK1/2, as the main explanations for effects reported in poorly vascularised tissues such as tendon (McGuire et al., 2025).

Pharmacokinetics

The first full ADME study, in rats and beagle dogs, found an elimination half-life of intact BPC-157 under 30 minutes, linear kinetics, and intramuscular bioavailability of about 14–19% in rats and 45–51% in dogs. The peptide was rapidly broken down to small fragments and amino acids and excreted in urine and bile (He et al., 2022). Our article on BPC-157 half-life covers these data in detail.

Human evidence

A PROSPERO-registered systematic review searched the literature to June 2026 and found three human studies with 30 participants in total: two retrospective case series and a two-person intravenous safety pilot. All were judged to be of poor methodological quality and the certainty of evidence was rated very low. The authors concluded that use outside regulated clinical trials is not supported (Poolton et al., 2026). A biopharmaceutical review the same year identified the lack of characterised formulations and validated pharmacokinetics as the main barrier to clinical development (Mateescu et al., 2026).

Evidence type	Volume	Quality
Cell and tissue studies	Extensive	Mechanistic; model-specific
Rodent injury models	Large number, mainly one research group	Consistent direction; independent replication limited
Formal pharmacokinetics	One two-species study	Good
Human studies	3 studies, n = 30	Very low certainty

Handling in the lab

Supplied as lyophilized powder; store at −20 °C, sealed and dark.
Water-soluble; reconstitute with bacteriostatic or sterile water. See how to reconstitute peptides.
Store solutions at 2–8 °C and avoid repeated freeze–thaw. See does BPC-157 need to be refrigerated?
Calculate concentrations with the peptide reconstitution calculator.

Related research

Frequently asked questions

What is BPC-157?